2021
Any day, split halfway: Flexibility in scheduling high‐dose cisplatin—A large retrospective review from a high‐volume cancer center
Kang JJ, Tchekmedyian V, Mohammed N, Rybkin A, Kitpanit S, Fan M, Wang H, Lobaugh SM, Zhang Z, Lee A, Chen L, Yu Y, Zakeri K, Gelblum DY, Riaz N, McBride SM, Tsai CJ, Cohen MA, Cracchiolo JR, Morris LG, Singh B, Patel S, Ganly I, Boyle JO, Wong RJ, Eng J, Zhi WI, Ng K, Ho AL, Dunn LA, Michel L, Fetten JV, Pfister DG, Lee NY, Sherman EJ. Any day, split halfway: Flexibility in scheduling high‐dose cisplatin—A large retrospective review from a high‐volume cancer center. International Journal Of Cancer 2021, 149: 139-148. PMID: 33586179, PMCID: PMC9380235, DOI: 10.1002/ijc.33518.Peer-Reviewed Original ResearchConceptsTotal cumulative doseHigh-dose cisplatinLocoregional failureOverall survivalOropharyngeal cancerDistant metastasisRegional failureHigh-volume cancer centerLocal failureAlternate dosing schedulesHuman papillomavirus (HPV) statusKarnofsky performance statusCooperative group trialsAdvanced oropharyngeal cancerLarge retrospective reviewStandard of careMultivariable regression modelsDefinitive chemoradiationInduction chemotherapyPerformance statusDosing schedulesTherapy startAdministration dayRetrospective reviewRenal toxicity
2019
Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer
Fan D, Ma J, Bell AC, Groen AH, Olsen KS, Lok BH, Leeman JE, Anderson E, Riaz N, McBride S, Ganly I, Shaha AR, Sherman EJ, Tsai CJ, Kang JJ, Lee NY. Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer. Cancer 2019, 126: 444-452. PMID: 31593317, PMCID: PMC7302673, DOI: 10.1002/cncr.32548.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapy, AdjuvantDose-Response Relationship, RadiationDoxorubicinFemaleFollow-Up StudiesHumansIndazolesMaleMiddle AgedPaclitaxelProgression-Free SurvivalPyrimidinesRadiotherapy DosageRadiotherapy, Intensity-ModulatedRetrospective StudiesSulfonamidesThyroid Carcinoma, AnaplasticThyroid GlandThyroid NeoplasmsThyroidectomyTumor BurdenConceptsLocoregional progression-free survivalRole of radiotherapyAnaplastic thyroid cancerTreatment of patientsOverall survivalAdverse eventsMetastatic diseaseTrimodal therapyThyroid cancerAcute grade 3 adverse eventsAdvanced anaplastic thyroid cancerGrade 3 adverse eventsPostoperative RTDistant metastasis-free survivalTrimodal treatment approachAcceptable toxicity profileProgression-free survivalLate adverse eventsLocal tumor controlMetastasis-free survivalLong-term outcomesLPFS ratesOS benefitConcurrent chemoradiationSystemic agents
2018
First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology
Kang JJ, Reiter RE, Steinberg ML, King CR. First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology. European Urology Oncology 2018, 1: 378-385. PMID: 31158076, DOI: 10.1016/j.euo.2018.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedFollow-Up StudiesHumansMaleMargins of ExcisionMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingNeoplasm, ResidualPostoperative PeriodPrognosisProstatectomyProstate-Specific AntigenProstatic NeoplasmsRadiotherapy, AdjuvantRetrospective StudiesRisk FactorsSalvage TherapySurvival AnalysisConceptsBone metastasis-free survivalProstate cancer-specific survivalUltrasensitive prostate specific antigenOverall survivalBiochemical relapseProstate-specific antigenRadical prostatectomyMultivariate analysisProstate-specific antigen levelImmediate adjuvant therapyOccult prostate cancerOccult systemic diseaseCancer-specific survivalEarly salvage radiotherapyHigh-risk diseaseKaplan-Meier methodTraditional risk factorsMetastasis-free survivalPrediction of outcomeProstate cancer pathologyAdjuvant therapySalvage radiotherapyHormone therapyIndependent predictorsStudy endpointWrong to be Right
Kang JJ, Reiter RE, Kummer N, DeKernion J, Steinberg ML, King CR. Wrong to be Right. American Journal Of Clinical Oncology 2018, 41: 1-5. PMID: 26237192, PMCID: PMC6946377, DOI: 10.1097/coc.0000000000000216.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnalysis of VarianceCohort StudiesDatabases, FactualDisease-Free SurvivalFollow-Up StudiesHumansKaplan-Meier EstimateMaleMargins of ExcisionMiddle AgedMultivariate AnalysisNeoplasm GradingNeoplasm Recurrence, LocalProportional Hazards ModelsProstatectomyProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesRisk AssessmentSalvage TherapySurvival AnalysisTreatment OutcomeConceptsSalvage radiation therapyRadical prostatectomyT stageCox multivariate analysisIntrinsic risk factorsIatrogenic failuresPostoperative PSASRT PSASalvage radiationBiochemical progressionIndependent predictorsLocal recurrencePreoperative PSARelapse rateBiochemical relapseKaplan-MeierBiochemical recurrenceSurgical approachRP patientsRisk factorsSurgical techniqueGleason gradeRadiation therapySurgical pathologyConsecutive rises